Lv4
518 积分 2025-09-17 加入
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
1小时前
待确认
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
1小时前
已关闭
Immunotherapy for hepatocellular carcinoma
2小时前
已完结
Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma
3小时前
已完结